Payment overview · 2025
General Payments
$1,858.24
91 reported records · 19 companies
Healthcare provider profile · identity verified
Mirela Draganescu, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HADDON TOWNSHIP, NJ · NPI 1932135696
Verified facts
What the public records show
CMS Open Payments records show Mirela Draganescu, M.D. received $1,858.24 in general payments during 2025 across 91 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $397.76 | 21.4% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $284.95 | 15.3% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $265.65 | 14.3% | 15 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $140.95 | 7.6% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $119.72 | 6.4% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $106.21 | 5.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $94.92 | 5.1% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $82.72 | 4.5% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $79.10 | 4.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.81 | 2.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.28 | 2.2% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $35.17 | 1.9% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $35.00 | 1.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.06 | 1.8% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $21.88 | 1.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.17 | 1.0% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $18.30 | 1.0% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.45 | 0.9% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $16.14 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,858.24 | 91 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $278.72 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $230.77 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $187.74 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $187.74 | 11 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $140.95 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $124.36 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $118.78 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $82.72 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $79.10 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $77.91 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $71.71 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $71.71 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $71.64 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $68.96 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $63.28 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $59.45 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $54.18 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $54.18 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $54.18 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.76 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $35.17 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $35.00 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $34.57 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.06 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.50 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $32.66 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $16.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
79 | 20 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
227 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1095 | 302 |
| Amlodipine Besylate | Amlodipine Besylate | 827 | 232 |
| Levothyroxine Sodium | Levothyroxine Sodium | 726 | 188 |
| Losartan Potassium | Losartan Potassium | 574 | 145 |
| Omeprazole | Omeprazole | 421 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 415 | 109 |
| Metformin Hcl | Metformin Hcl | 405 | 107 |
| Gabapentin | Gabapentin | 384 | 96 |
| Lisinopril | Lisinopril | 315 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 281 | 75 |
| Alprazolam | Alprazolam | 236 | 54 |
| Eliquis | Apixaban | 227 | 47 |
| Simvastatin | Simvastatin | 227 | 66 |
| Tramadol Hcl | Tramadol Hcl | 224 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 222 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 221 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 215 | 68 |
| Furosemide | Furosemide | 203 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 197 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 53 |
| Carvedilol | Carvedilol | 188 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 180 | 63 |
| Meloxicam | Meloxicam | 173 | 48 |
| Alendronate Sodium | Alendronate Sodium | 169 | 50 |
| Trazodone Hcl | Trazodone Hcl | 162 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 160 | 38 |
| Montelukast Sodium | Montelukast Sodium | 158 | 47 |
| Sertraline Hcl | Sertraline Hcl | 156 | 45 |
| Pioglitazone Hcl | Pioglitazone Hcl | 152 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 39 |
| Potassium Chloride | Potassium Chloride | 149 | 37 |
| Januvia | Sitagliptin Phosphate | 148 | 28 |
| Clonazepam | Clonazepam | 143 | 38 |
| Buspirone Hcl | Buspirone Hcl | 133 | 37 |
| Famotidine | Famotidine | 125 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 121 | 32 |
| Glipizide | Glipizide | 117 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 38 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 107 | 24 |
| Ezetimibe | Ezetimibe | 105 | 35 |
| Ibuprofen | Ibuprofen | 105 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 27 |
| Bupropion Xl | Bupropion Hcl | 92 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 21 |
| Lorazepam | Lorazepam | 88 | 27 |
| Naproxen | Naproxen | 86 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 84 | 12 |
| Hydrocortisone | Hydrocortisone | 80 | 24 |
| Synthroid | Levothyroxine Sodium | 79 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 76 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 74 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 22 |
| Ozempic | Semaglutide | 72 | 16 |
| Glimepiride | Glimepiride | 71 | 24 |
| Farxiga | Dapagliflozin Propanediol | 69 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 68 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 17 |
| Pregabalin | Pregabalin | 68 | 16 |
| Donepezil Hcl | Donepezil Hcl | 66 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | 11 |
| Xarelto | Rivaroxaban | 60 | 14 |
| Allopurinol | Allopurinol | 59 | 18 |
| Finasteride | Finasteride | 58 | 18 |
| Methenamine Hippurate | Methenamine Hippurate | 58 | suppressed |
| Diazepam | Diazepam | 57 | 13 |
| Bydureon Bcise | Exenatide Microspheres | 55 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 52 | 16 |
| Mirtazapine | Mirtazapine | 52 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 12 |
| Doxepin Hcl | Doxepin Hcl | 51 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | suppressed |
| Atenolol | Atenolol | 44 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 15 |
| Topiramate | Topiramate | 44 | 12 |
| Azithromycin | Azithromycin | 43 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 14 |
| Chlorthalidone | Chlorthalidone | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | 11 |
| Labetalol Hcl | Labetalol Hcl | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | 17 |
| Meclizine Hcl | Meclizine Hcl | 40 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 15 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Myrbetriq | Mirabegron | 36 | 12 |
| Tradjenta | Linagliptin | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Spironolactone | Spironolactone | 33 | 11 |
| Celecoxib | Celecoxib | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 24 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Nystatin | Nystatin | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 23 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Linzess | Linaclotide | 27 | 13 |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Repaglinide | Repaglinide | 27 | 11 |
| Valsartan | Valsartan | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 21 |
| Nyamyc | Nystatin | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 19 |
| Methimazole | Methimazole | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 12 |
| Vilazodone Hcl | Vilazodone Hcl | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 11 |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | 13 |
| Procto-Med Hc | Hydrocortisone | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | 11 |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Bumetanide | Bumetanide | 15 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Metolazone | Metolazone | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,858.24 · 91 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, AUSTEDO XR, BREZTRI, COMIRNATY, Cologuard Collection Kit, FARXIGA, Flector, KISUNLA, LOREEV XR, Leqembi, Licart, MOUNJARO, NEFFY, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, Tirosint, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error